Tandem Diabetes Care Reports Record Third-Quarter Sales

Tandem Diabetes Care ( (TNDM) ) has released its Q3 earnings. Here is a breakdown of the information Tandem Diabetes Care presented to its investors.

Tandem Diabetes Care, Inc. is a global company specializing in the development and sale of advanced insulin delivery systems, primarily serving the diabetes technology sector. The company is known for its innovative products like the Tandem Mobi and t:slim X2 insulin pumps, which incorporate advanced hybrid closed-loop technology.

In its third-quarter 2025 financial report, Tandem Diabetes Care announced record sales both domestically and internationally, alongside improvements in gross margins. The company highlighted significant strategic advancements, including increased pharmacy benefit coverage for its products and the FDA clearance for extended wear use of its SteadiSet Infusion Set.

Key financial metrics for the third quarter of 2025 showed worldwide sales reaching $249.3 million, a slight increase from the previous year. The company reported a GAAP gross profit of $134.3 million, with a gross margin of 54%, up from 51% in the prior year. Despite these gains, Tandem reported a GAAP net loss of $21.2 million, a slight improvement from the previous year’s loss.

Strategically, Tandem has made strides in expanding its product offerings and market reach. The company began the global rollout of its t:slim X2 pump integrated with the FreeStyle Libre 3 Plus CGM sensor and filed for FDA clearance for Android mobile control of its Tandem Mobi system.

Looking ahead, Tandem Diabetes Care reaffirms its 2025 financial guidance, projecting full-year sales of approximately $1.0 billion with a gross margin of 53% to 54%. The company remains focused on achieving its strategic goals while continuing to enhance the lives of people with diabetes through its innovative technologies.